Project Grant R01CA298925
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$602K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award R01CA289576 was provided by the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program, to the University of Colorado-Denver. The $566,523 grant, awarded on December 5, 2024, will fund research to identify key mechanisms and interception targets in persistent lung pre-malignant lesions that are likely to progress to lung cancer. The goal is to develop targeted prevention approaches to intercept the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models. The $160,330 award, effective December 1, 2024 through November 30, 2026, aims to:
Introduce oncogenic mutations into primary human lung stem and progenitor cells to generate organoid models for high-throughput drug testing.
Xenograft the mutated stem/progenitor cells into immunodeficient mouse lungs to develop an...
This federal Project Grant award of $158,365 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) will support research to understand the impact of NRF2 activation on the initiation and progression of lung squamous cell carcinoma (LUSC). The University of North Carolina at Chapel Hill will develop a novel genetically-engineered mouse model to assess how NRF2 activation affects LUSC incidence, tumor characteristics, and the tumor microenvironment....
This National Cancer Institute (NCI) Project Grant award under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $968,999 to the University of North Carolina at Chapel Hill (UNC-CH) to optimize lung cancer surveillance strategies. The key objectives are to: 1) examine real-world effectiveness of imaging surveillance practices among lung cancer survivors after curative-intent surgery, 2) develop and validate risk prediction models incorporating novel imaging biomarkers...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $352,275 to the Regents of the University of Minnesota to develop a novel mitochondria-targeted drug, MITOMET, for the prevention and treatment of lung cancer with KRAS and LKB1 gene mutations. The key objectives are to:
Assess the safety and efficacy of MITOMET in suppressing the progression of tobacco smoke-induced lung tumors in...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Icahn School of Medicine at Mount Sinai to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC). The project aims to: 1) determine how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance of epigenomic SCLC states, 2) determine the mechanisms for pulmonary to neuronal...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research aimed at developing effective therapeutic strategies for lung cancers with SMARCA4 genetic deficiencies. The primary grantee, The Trustees of Columbia University in the City of New York, will receive $557,418 over the award period from March 2025 to February 2030. The research will use genetically engineered mouse models to assess the impact of...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to investigate a novel tumor suppressive pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to elucidate the biological roles of the stress-activated protein kinase (SAPK) axis in...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $627,833 Project Grant to The University of Texas Southwestern Medical Center to develop an informatics platform that integrates molecular and pathology data from various lung cancer preclinical models and patient tumors. The goal is to establish a cross-comparison platform to assess the fidelity of preclinical lung cancer models in relation to human tumors.
The project has three specific aims: 1) Harmonize...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...